News

April 7, 2020
Toronto - April 7, 2020 - The following is a statement from Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada on COVID-19 and the supply of generic and biosimilar medicines to Canadian hospitals: “Member companies of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada are working with our partners in government and the pharmaceutical supply chain to mitigate shortages of medicines used in Canada’s hospitals due to increases in demand resulting from the COVID-19 outbreak.
Read more
April 1, 2020
Toronto - April 1, 2020 - The following is a statement from Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada on COVID-19: “The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada continue to work closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.
Read more
March 18, 2020
Toronto - March 18, 2020 - The following is a statement from Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada on COVID-19: “The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada are working closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.
Read more
March 11, 2020
Toronto - March 11, 2020 - The following is a statement from Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada, on COVID-19: “The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada are working closely with Health Canada and our member companies to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.
Read more
December 12, 2019
Toronto – December 12, 2019 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of Alberta for becoming the second province in Canada to implement a biosimilar “switching” or transitioning program.
Read more
September 6, 2019
Toronto – September 6, 2019 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of British Columbia for building on the success of its biosimilar switching program and called on other provinces to implement similar programs.
Read more
June 12, 2019
Toronto – June 12, 2019 – The Advisory Council on the Implementation of National Pharmacare’s Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.
Read more
May 27 2019
Toronto – May 27, 2019 - Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of British Columbia for announcing a program in which patients taking originator biologic drugs will be “switched” or transitioned by their clinicians to a biosimilar biologic drug within a six-month period.
Read more
Nov 22 2018
Toronto - November 22, 2018 - Biosimilars Canada, the national association representing Canada's biosimilar medicines industry, today announced that Innomar Strategies, Canada's leading specialty pharmaceuticals service provider has been selected as the preferred provider for the Biosimilars Canada Patient Support Program (PSP) platform. The platform will provide a common suite of PSP services for Biosimilars Canada members going forward that can be customized to meet the individual needs of the therapy, the biosimilar sponsor and payers.
Read more
January 9, 2017
TORONTO, January 9, 2017 - Jim Keon, President of Biosimilars Canada, issued the following statement regarding the release of the revised Guidance Document, Information and Submission Requirements for Biosimilar Biologic Drugs:
Read more
April 7, 2015
Toronto, April 7, 2015 - The Canadian Generic Pharmaceutical Association (CGPA) announced today the establishment of a new CGPA Biosimilars Board and the election of Michel Robidoux, President and General Manager of Sandoz Canada, as its inaugural Chair.
Read more